Research · Sep 3, 2026
[ELPC] Elevance Health Tracking-Stock Thesis 2026: Anthem-Blue-Cross-Blue-Shield + Carelon-Health-Services Compounder
Elevance Health Tracking-Stock (NYSE: ELPC) is a tracking-stock related to the Indianapolis-IN-headquartered Health-Insurance-and-Anthem-Blue-Cross-Blue-Shield + emerging-multi-cycle-Carelon-Health-Services leader (Elevance-Health-Inc-ELV, formerly Anthem-Inc) providing distinctive multi-cycle Anthem-Blue-Cross-Blue-Shield-Health-Insurance + emerging-Medicare-Advantage + emerging-Medicaid + emerging-Carelon-Health-Services + emerging-CarelonRx services to substantial multi-cycle ~47-50-million-Member-14-State-Blue-Cross-Blue-Shield-Health-Insurance-Customer base. The company has distinctive multi-cycle Elevance-Health-and-Indianapolis-IN-and-Anthem-Blue-Cross-Blue-Shield heritage: founded 1944 as Anthem-Insurance-Mutual-of-Indiana-Founder-and-Blue-Cross-Blue-Shield-Indiana; 2001 NYSE Anthem-Inc-IPO; 2004 substantial WellPoint-Health-Networks-acquired-Anthem-WellPoint-Inc-merged ($16.5B providing California-Blue-Cross-and-multi-state-Blue-Cross-Blue-Shield); 2014 substantial WellPoint-renamed-Anthem-Inc; 2022 substantial Anthem-Inc-renamed-Elevance-Health-Inc-ELV; 2017 Gail-K-Boudreaux-CEO; 2024-substantial-Carelon-Health-Services-growth; multi-cycle-disciplined-bolt-on-Health-Insurance-and-Carelon-Health-Services-acquisitions. FY2025 closes with selected various aggregate revenue ~$180-200B (~3-7% YoY-growth + emerging-multi-cycle-Health-Insurance-and-Anthem-Blue-Cross-Blue-Shield-and-Carelon-Health-Services-growth), adjusted EBITDA ~$11.5-13.5B (~6-7% margins reflecting Health-Insurance-Managed-Care economics), adjusted EPS ~$35-42, net debt ~$28-31B (~2.0-2.5x leverage), and ~225-228M shares outstanding under President & CEO Gail K. Boudreaux. The Anthem-Blue-Cross-Blue-Shield-Health-Benefits-and-Carelon-Health-Services franchise deep-dive covers distinctive multi-cycle ~104,000+ employees + ~14-State-Blue-Cross-Blue-Shield-License-Office (California + Colorado + Connecticut + Georgia + Indiana + Kentucky + Maine + Missouri + Nevada + New-Hampshire + New-York + Ohio + Virginia + Wisconsin), Health-Benefits ~84-87% revenue (Commercial + Individual-Exchange + Medicare-Advantage + Medicaid + Federal-Employee-Program-FEP) + Carelon-Health-Services ~13-16% revenue (CarelonRx-Pharmacy-Benefit-Manager + CarelonInsights + CarelonGlobal-Solutions + Behavioral-Health-Diagnostic-Imaging-Post-Acute-Care), substantial ~47-50-million-Member customer base, 2001-NYSE-Anthem-Inc-IPO + 2004-WellPoint-merged + 2014-WellPoint-renamed-Anthem-Inc + 2022-Anthem-Inc-renamed-Elevance-Health-Inc-ELV + 2024-Carelon-Health-Services-growth transformational-platform, emerging-multi-cycle Medicare-Advantage-Aging-Demographic + emerging-Medicaid-State-Managed-Care + emerging-Commercial-Group-Employer + emerging-Individual-Exchange-ACA + emerging-Carelon-Health-Services + emerging-GLP-1-Anti-Obesity-Drug-Coverage structural-tailwinds, competing in US-Health-Insurance space with UnitedHealth Group, CVS Caremark/Aetna, Cigna Group/Evernorth, Humana, Centene, Molina, HCSC, GuideWell-Florida-Blue, Blue Shield of California, CareSource, Independence Health, Highmark, BCBS Tennessee, Premera, Regence, Kaiser Permanente, Triple-S/Innovacare, Bright Health/NeueHealth, Oscar Health, and private-equity-Apollo-Carlyle-Bain-KKR-Blackstone-CDR-Veritas-Genstar-American-Securities-CCMP-Stone-Point-Lovell-Minnick-Hellman-Friedman-Silver-Lake-TPG-Reverence-Warburg-Pincus-Ares-Centerbridge-GTCR-Linden-Avista-NEA. The Gail-K-Boudreaux + multi-decade compounder thesis + 14-State-Blue-Cross-Blue-Shield-License deep-dive covers Gail-K-Boudreaux-CEO (~30+ year longtime-Health-Insurance-and-UnitedHealth-and-Aetna-and-Wellpoint-veteran) expertise, 1944-Anthem-Insurance-Mutual-of-Indiana + 2001-NYSE-Anthem-Inc-IPO + 2004-WellPoint + 2014-WellPoint-renamed-Anthem-Inc + 2022-Anthem-Inc-renamed-Elevance-Health-Inc-ELV + 2024-Carelon-Health-Services-growth transformational-platform, multi-cycle reliable-and-emerging-growing-dividend (~$6.40/yr, ~1.5-2.2% yield, ~14+ year continuous) + multi-cycle-substantial-share-buyback (~$2.5-5.0B/yr). Capital position is IG-equivalent (A2/A to A3/A- ~2.0-2.5x leverage). At ~$380-475 per share, equity value ~$85.5-108.0B, EV ~$115-140B, providing ~10-14x EPS and ~9-12x EV/EBITDA.